Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2023 Earnings Call Transcript August 9, 2023 Ionis Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.6, expectations were $-0.94. Operator: Good morning, and welcome to Ionis’ Second Quarter 2023 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn […]
/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of.
Ionis Pharmaceuticals (IONS) Reports Positive Data from GSK's Phase 2b Study of bepirovirsen streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.